C
ardiac magnetic resonance (CMR) has made major inroads in the past 2 decades thanks to its ability to characterize myocardial tissue noninvasively (1) . It began with late gadolinium enhancement as a means to assess myocardial infarct size (2) , for which it is now the gold standard. Over Native T1 is especially useful in patients who cannot receive gadolinium-based contrast agents because of stage 4 or 5 chronic kidney disease. Native T1 is highest in patients with amyloidosis, many of whom have chronic kidney disease (6) . It is elevated to an intermediate degree in hypertrophic cardiomyopathy and other nonischemic cardiomyopathies (7). Postcontrast T1 mapping is used to calculate extracellular volume (ECV), which is elevated in the setting of interstitial fibrosis or other causes of increased extracellular space such as edema and/or inflammation (1). Elevated ECV has been documented in hypertensive heart disease (8), hypertrophic cardiomyopathy (9) , and heart failure with preserved ejection fraction (10) . Increased ECV has been associated with adverse short-term cardiac prognosis in a diverse patient population (11).
T1 mapping is an extremely versatile technique.
This issue of iJACC is dedicated to a variety of applications and potential uses of T1 mapping in cardiovascular disease. The promise is remarkable and increasingly tangible. For example, the group at Oxford has studied native T1 at rest and with adenosine stress, showing that native T1 is sensitive to changes in myocardial blood volume, which may be a sensitive marker of ischemia (12) . They found that normal myocardium increased native T1 with adenosine by more than 6%, whereas infarcted myocardium showed essentially no increase. 
